Form 4: RxSight CFO Receives Stock Grant
Insider Transaction (Form 4)
Mark Wilterding, Chief Financial Officer of RxSight, Inc., reported multiple transactions in common stock on September 5, 2026.
Summary
- Disposition to the issuer: disposed of 258,770 Stock Option (right to buy) on September 5, 2026 (Direct).
- Grant/award: acquired 258,770 Stock Option (right to buy) on September 5, 2026; holds 258,770 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Mark Wilterding — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-05 | Disposition to the issuer | Stock Option (right to buy) | 258,770 | — | — | 0 |
| 2026-09-05 | Grant/award | Stock Option (right to buy) | 258,770 | — | — | 258,770 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-05 | Disposition to the issuer (258,770 shares) |
| 2026-09-05 | Grant/award (258,770 shares) |
Keywords
insider transaction, Form 4, RXST, RxSight, Inc., neutral, Mark Wilterding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.